KR20160082317A - A composition for skin comprising extract of Lonicera caerulea fruits - Google Patents

Abstract

The present invention relates to a composition for skin anti-aging, skin regeneration, skin wrinkle amelioration, skin whitening, or skin moisturization, containing a Lonicera caerulea var. edulis Turcz. ex Herder fruit extract as an active ingredient. The present invention further relates to a pharmaceutical composition for skin regeneration or skin whitening, and quasi-drugs for skin improvement.

Description

[0001] The present invention relates to a composition for skin, which comprises extracts of Lonicera caerulea fruits,

The present invention relates to a method for producing Lonicera The present invention relates to a cosmetic composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing, comprising a fruit extract as an active ingredient, a pharmaceutical composition for skin regeneration or skin whitening, and a quasi-drug for skin improvement.

Skin is the primary barrier of the human body. It protects the internal organs of the body from external stimuli such as temperature and humidity changes, ultraviolet rays, and pollutants, and plays an important role in keeping the body homeostatic such as body temperature control. This important skin also becomes aged gradually as the age of the human body grows, and as a result, skin elasticity loss, keratinization, wrinkle formation, skin atrophy and the like appear.

Much research has been carried out on the importance and role of collagen directly affecting such wrinkles and skin elasticity. When the majority of the skin, 77% of the skin, and 90% of the dermis are rich in quantity and quality of collagen, the skin can be healthy and beautiful without wrinkles and sagging. Conventionally, collagen has been commercialized in cosmetics. However, when collagen is applied to the skin surface as a cosmetic, it is difficult to absorb the transdermal absorption of collagen, which is a polymer, so that the function thereof can not be sufficiently expected.

On the other hand, as a pigment present in the epidermis of the skin, melanin is made from melanocytes existing in the basal layer of the epidermis and transferred to epidermal cells called keratinocytes.

Depending on the amount of melanin produced, it can cause various diseases. When melanin is accumulated too much due to excessive synthesis of melanin due to sunlight, hormonal changes, inflammation, medicines or the like and melanin accumulation is not performed smoothly, it not only damages the skin but also deposits spots and freckles, It also causes skin cancer from the same lesion. Therefore, in order to prevent such pigment deposition phenomenon, it is necessary to inhibit a part of the melanin production process to reduce the production of melanin.

On the other hand, development of whitening agents for the treatment of skin pigmentation abnormalities and for satisfying aesthetic desires is actively carried out. Currently, in the development of a whitening agent for skin cosmetics, there is known a method of decolorizing by reducing the produced melanin pigment and a method of inhibiting the activity of tyrosinase, an enzyme that forms a melanin pigment. As a whitening ingredient in the conventional cosmetics field, for example, substances inhibiting tyrosinase enzyme activity such as kojic acid and arbutin, hydroquinone, vitamin C and derivatives thereof, various plant extracts Has been used. However, the use of such whitening ingredients is limited due to poor stability in the preparation, coloration by decomposition, generation of offensive odor, efficacy at a biological level, unclear effect and stability, and the like.

On the other hand, the skin has a barrier function that protects the body from various external stimuli while blocking the inner moisture. However, people tend to have increased dry skin with age, especially women, because of decreased secretion of estrogen, which is a female hormone, at age, sebum secretion is not smooth and the oil and water balance is destroyed, It tends to lead to aging.

Also, in general, environmental pollution becomes serious, owing to the increase of ultraviolet radiation due to ozone layer destruction, drying of living space, personal allergic constitution, stress and increase of chemical harmful substances, skin is easily damaged, And the skin is easily reddened or sensitized. Recently, research has been reported in which the expression of proteins in the skin becomes abnormal due to heat applied to the skin, skin aging due to aging due to increase of active oxygen, and decomposition of elastic fibers is disclosed in Patent Document 10-2006-0113112 Invest, Dermatol, 124, 70-78, 2005).

Various cosmetic compositions using various moisturizing agents such as oils, sugars and polyols have been developed in order to improve the dryness of the skin due to an increase in ultraviolet ray dose, drying of living space, stress and increase of chemical harmful substances. For example, by using ceramide, cholesterol, fatty acid and so on, it strengthens the skin barrier function to suppress the moisture evaporating from the skin or to absorb moisture of the skin by using sugar, polyol and the like, To enhance the moisturizing effect of the skin. However, it is difficult to maintain the effect for a long period of time in a low relative humidity, and it is rather uncomfortable in a summer when the relative humidity is high, making it difficult to produce an appropriate cosmetic composition according to a change in relative humidity.

On the other hand, daengdaengyi trees (Lonicera caerulea ) fruit has been used in folk remedies in northern Russia, China and Japan, but is rarely known as edible fruit in North America, Europe and Korea and has been shown to prevent skin senescence, skin regeneration, skin wrinkles, There is no known skin moisturizing effect.

Accordingly, the present inventors have made intensive efforts to develop a composition having an effect on skin cosmetic and skin-related diseases while being excellent in stability. As a result, it has been found that the extract of Tofu is effective in prevention of skin aging, skin regeneration, skin wrinkle improvement, skin whitening, The present invention has been accomplished by confirming that the present invention can be effectively used for cosmetic and skin-related diseases,

It is an object of the present invention to provide a method for the production of Lonicera The present invention provides a cosmetic composition for skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening,

Another object of the present invention is to provide a pharmaceutical composition for skin regeneration or skin whitening comprising the extract as an active ingredient.

It is still another object of the present invention to provide a quasi-drug for skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing containing the extract as an active ingredient.

Yet another object of the present invention is to provide a health functional food composition containing the above extract as an active ingredient for preventing skin aging, regenerating skin, improving skin wrinkles, skin whitening or skin moisturizing.

It is still another object of the present invention to provide a method for preventing skin aging, which comprises the step of administering the extract to a subject.

Yet another object of the present invention is to provide a method for regenerating skin comprising the step of administering the extract to a subject.

It is a further object of the present invention to provide a method of improving skin wrinkles comprising the step of administering the extract to a subject.

It is still another object of the present invention to provide a skin whitening method comprising the step of administering the extract to a subject.

Yet another object of the present invention is to provide a skin moisturizing method comprising the step of administering the extract to an individual.

The present invention as an embodiment for achieving the abovementioned objects is daengdaengyi tree (Lonicera The present invention provides a cosmetic composition for prevention of skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing, which comprises a fruit extract of coriander oil or caerulea as an active ingredient.

In the present invention, " Lonicera caerulea ") is a deciduous broad-leaved shrub with a height of 1.5m and is divided into branches with many branches, shield-shaped bracts on the branches of small branches, white parts of the trunk are white, The flower is usually short in peduncle and run on the axil, and the corolla is funnel-shaped with a pale yellowish white color and blooms in the summer. The calyx is divided into 5 pieces like a mount, the corolla is yellowish white, circular bell shape, length is 1.2 to 1.5cm, and there is a little hair, and the operation is shorter than the style, there is no hair, and the two are combined. Is known to be a cold-tolerant plant distributed in Siberia, Sakhalin, northern China, Tibet, and North Korea.

The fruit of the buttock tree is elliptical or almost circular, and is dark brown in July to August and covered with white powder. In the pharmacological activity of the above-mentioned Butterfly tree, the effect of preventing and treating hepatitis, liver cirrhosis or fatty liver disease and the hangover of the butt-nut fruit of Thunbergii fruit extract is known, but the thyroid function There is no known method for the prevention or treatment of thyroid diseases such as hypothyroidism, hyperthyroidism, thyroiditis, or thyroid nodules, which were first identified by the present inventors. In the present invention, it is possible to use commercially available commercially-available or commercially available naturally-harvested or cultivated nuts.

In the present invention, "farina tree fruit extract" refers to all of the extracts obtained by extracting from the feather tree fruit. The isotonic extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and may include an extract, a dry powder thereof, or any form thereof formulated therewith have. The extraction method may be, but not limited to, hot water extraction, cold extraction, reflux extraction, or ultrasonic extraction. In the present invention, the isola extract is used in combination with BHcL.

In obtaining the royal jelly extract, it is preferably extracted with water, an organic solvent or a mixed solvent thereof.

When extracting using an organic solvent, there may be mentioned, but not limited to, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, Organic solvents such as amide (DMF), dimethylsulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof may be used. The active ingredient of the herbal medicine may be used at room temperature . Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient of the medicament may differ. Therefore, an appropriate organic solvent should be selected and used.

The solvent extract may further comprise a step of filtering the extract to remove suspended solid particles. Ultrafiltration, freeze filtration, centrifugation or the like may be used, but the present invention is not limited thereto.

Concentration of the extract can be carried out by reduced-pressure concentration, reverse osmosis concentration, or the like. The post-concentration drying step includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, or infrared drying. In some cases, it may further comprise a step of pulverizing the finally dried extract.

In addition, the extract may be subjected to an additional fractionation process. For example, the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction with a nonpolar organic solvent, for example, hexane, ether, dichloromethane, chloroform, ethyl acetate or a mixed solvent thereof, Concentrated and / or dried.

As a specific example, water of 5 to 25 times, preferably 7 to 15 times, water of carbon number 1 (C ₁ ) to carbon number 4 (C) of the dry weight (kg) of the soya nut which provides the above- ₄ ) lower alcohol or a mixed solvent thereof, preferably water or a mixed solvent of water and ethyl alcohol; At an extraction temperature of from 20 to 100 캜, preferably from 60 to 100 캜; 0.5 hours to 2 days, preferably 1 hour to 1 day; Hot water extraction, cold extraction, ultrasonic extraction, reflux extraction, preferably reflux extraction; And then successively extracted once to five times, preferably twice to three times. Further, the extract is filtered through a filter paper, and the filtrate is concentrated under reduced pressure at 20 to 100 ° C, preferably 50 to 70 ° C with a rotary vacuum concentrator, and then dried to produce Powdery Thickberry fruit extract. Powdered royal jelly extract can be used as is or dissolved in a certain concentration in a solvent. However, the present invention is not limited to the above examples.

According to one specific embodiment of the present invention, the royal jelly extract can be used for skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing.

As used herein, the term "prevention of skin aging" means preventing or delaying the degeneration of skin tissue due to physiological changes of the body occurring over time. In order to inhibit skin aging, it is necessary not only to protect the skin from external harmful environment but also to supply moisture to the skin appropriately and activate skin cells to promote synthesis of biosynthetic proteins such as collagen and elastin The formation of wrinkles should be suppressed as much as possible. Particularly in the structure of the skin, collagen in the dermis layer and elastin in the elastic fiber form a network structure. As the network structure is broken, the elastin is decomposed by the decomposing enzyme, elastase, Which causes aging of the inner skin. Therefore, skin aging can be suppressed by inhibiting decomposition of elastin, which is one of the main causes of skin aging.

As used herein, the term "skin regeneration" refers to the recovery process of the skin tissue against damage caused by external and internal causes of the skin. The damage caused by the external cause may be ultraviolet rays, external contaminants, wound, trauma, and the damage caused by the internal cause may be stress.

As used herein, the term "improvement of skin wrinkles" means maintaining or strengthening the wrinkles and elasticity of the skin. Collagen which is a collagen fiber of the dermal layer of skin and elastin which is a resilient fiber play a key role in the skin as a main protein and thus have an effect of inhibiting elastase activity and / or collagenase activity The wrinkle-improving effect can be exhibited.

The term "skin whitening " of the present invention refers to the function of increasing the number of melanocytes in the skin and thereby preventing excessive deposition of melanin pigment on the skin, or thinning the melanin pigment previously deposited. As a result, it is possible to inhibit spots and freckles caused by excessive deposition of melanin pigment.

The term "skin moisturizing" of the present invention refers to the formation of a film on the skin which will enhance the ability of the skin to retain the moisture already present in the skin.

The farinacea fruit extract of the present invention promotes the synthesis of collagen type I and inhibits hyaluronidase, elastase, collagenase and / or MMP-1, Prevention, skin regeneration and anti-wrinkle effect. In addition, the extract may inhibit tyrosinase and inhibit the formation of melanin in melanoma to exhibit a whitening effect. Further, the extract may exhibit a moisturizing effect.

In conclusion, the cosmetic composition containing the extract of Staphylococcus aureus as an active ingredient of the present invention can exhibit excellent skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening and / or skin moisturizing.

In the present invention, the above-described Tofu extract may be contained in an appropriate amount to exhibit the above-described effects.

The cosmetic composition according to the present invention may contain various components commonly used in external preparations for skin such as water-soluble components, powder components, oils, fats and oils, as long as the effect of the present invention is not impaired, A surfactant, a moisturizer, a viscosity adjusting agent, an antiseptic, an antioxidant, a perfume, a pigment, and the like.

The formulation of the cosmetic composition according to the present invention may be selected arbitrarily and may be selected from the group consisting of water, physiological saline, glycerol, oil fractions, surfactants, moisturizers, thickeners, chelating agents, pigments, preservatives and perfumes A cosmetic composition in the form of lotions, liquid preparations, emulsions, emulsions, suspensions, tablets and capsules mixed with the known excipients for cosmetic compositions . The cosmetic composition may be used to prepare cosmetic compositions such as foundation lotion, lipstick, mascara or make-up base such as soft lotion, milk lotion, nutrition cream, massage cream, essence, cleansing foam, cleansing water, And can also make cleansers and bath preparations.

In order to accelerate the absorption and fixation of the royal juniper fruit extract of the cosmetic composition in the skin, the cosmetic composition containing the royal jelly extract may be composed of 1 to 7% by weight of glycerin in the excipient for cosmetics, but is not limited thereto.

In addition, sunflower oil may be included in cosmetic excipients to provide an antioxidant function to the cosmetic composition, but is not limited thereto.

The present invention as another aspect is daengdaengyi tree (Lonicera The present invention also provides a pharmaceutical composition for skin regeneration or skin whitening, which comprises a fruit extract of Corynebacterium sp . caerulea as an active ingredient.

The royal jelly extract, skin regeneration and skin whitening are as described above.

The composition of the present invention promotes the synthesis of collagen type I and can inhibit hyaluronidase, elastase, collagenase and / or MMP-1, Can inhibit tyrosinase and inhibit the formation of melanin in melanoma, and thus can be used as a pharmaceutical composition for skin regeneration and skin whitening.

And can be used in the treatment of impotence according to the skin regeneration effect and can be used for the prevention or treatment of diseases such as melanoma, spots and freckles which require reduction of melanin according to the skin whitening effect.

The throughput of the pharmaceutical composition for skin regeneration or skin whitening used in the present invention should be a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and the effective dose level will vary depending on the species and severity, The type of disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. Effective amounts may vary depending on the route of treatment, the use of excipients, and the likelihood of use with other agents, as will be appreciated by those skilled in the art.

The pharmaceutical compositions for skin regeneration or skin whitening of the present invention may be prepared into pharmaceutical formulations using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal.

Therefore, the pharmaceutical composition of the present invention can be formulated and used in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like oral preparation, external preparation and patch according to a conventional method, Excipients or diluents conventionally used in the manufacture of pharmaceutical compositions.

Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, a weighting agent, a binder, a wetting agent, a disintegrant, a surfactant, and the like is usually used.

In yet another aspect the invention daengdaengyi tree (Lonicera caerulea ) as an active ingredient to provide anti-aging, skin regeneration, skin wrinkle improvement, skin whitening or quasi-quasi-skin for skin moisturizing.

The extracts of soya nut, anti-aging of skin, skin regeneration, skin wrinkle improvement, skin whitening and skin moisturizing are as described above.

The term "quasi-drug" in the present invention means a fiber, a rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or an animal, a weak action on the human body, Or products similar to those which are not machinery, preparations used for sterilization, insecticides and similar uses for the prevention of infections, for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases of human beings or animals Machinery, or apparatus, and that is not an apparatus, machine, or apparatus of an article used for the purpose of giving pharmacological effects to the structure or function of a person or animal, It also includes supplies.

The external preparation for skin is not particularly limited, but may be preferably used in the form of an ointment, a lotion, a spray, a patch, a cream, a powder, a suspension, an gel or a gel. Such personal care products include but are not limited to soap, cosmetics, wet tissue, tissue paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, makeup, foundation, ball touch, mascara, eye shadow, , A hair care product, an air freshner gel or a cleaning gel. Further, another example of the quasi-drug composition of the present invention is a disinfectant cleaner, a shower foam, a gagrin, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment agent or a filter filler.

In yet another aspect the invention daengdaengyi tree (Lonicera The present invention provides a health functional food composition containing skin extract, fruit extract, and extract of Corynebacterium as an active ingredient for preventing skin aging, regenerating skin, improving skin wrinkles, skin whitening or skin moisturizing.

The extracts of soya nut, anti-aging of skin, skin regeneration, skin wrinkle improvement, skin whitening and skin moisturizing are as described above.

When the composition of the present invention is used as a health functional food additive, the composition may be added as it is or may be used together with other health functional foods or health functional food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use. Generally, the composition of the present invention may be added in an amount of preferably not more than 15 parts by weight, more preferably not more than 10 parts by weight, based on the raw material, in the production of food or beverage. However, in the case of long-term intake intended for health control and hygiene, the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount in the above range.

There is no particular limitation on the kind of the health functional food of the present invention. Examples of the health functional food to which the composition can be added include dairy products such as meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen and other noodles, gums, ice cream, Alcoholic beverages, and vitamin complexes, and may include all the health functional foods in the conventional sense, and foods used as feeds for animals.

In addition, when the health functional food composition of the present invention is used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages. The natural carbohydrates may be polysaccharides such as disaccharides such as monosaccharides such as glucose and fructose, maltose, sucrose, dextrin, cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. The ratio of the natural carbohydrate is not limited thereto, but may be about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention. The sweeteners may be natural sweeteners such as tau martin and stevia extract, and synthetic sweeteners such as saccharin and aspartame.

In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.

In yet another aspect the invention daengdaengyi tree (Lonicera The present invention provides a method for preventing skin aging, a method for regenerating skin, a method for improving skin wrinkles, a skin whitening method, and a skin moisturizing method, which comprises the step of administering to a subject a fruit extract of C. caerulea .

The composition of the present invention containing the extract of royal jellyfish fruit as an active ingredient can be used as a cosmetic composition for skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing.

Figures < RTI ID = 0.0 &gt; (Fig. 1A), LFs (Fig. 1B) and LFi (Fig. 1C) on human fibroblast survival rate. Cells were treated with 0 (control), 1.25, 2.5, 5, 10, 100 and 500 mg / ml of BHcL, LFs or LFi and cultured for 24 hours, followed by MTT treatment for an additional 4 hours. Each value represents the mean ± SD of five independent experiments.
Figures 2a to 2c show the effect of BHcL (Figure 2a), LFs (Figure 2b) and LFi (Figure 2c) on B16 / F10 murine melanoma cell viability. Cells were treated with 0 (control), 1.25, 2.5, 5, 10, 100 and 500 mg / ml of BHcL, LFs or LFi and incubated for 24 hours, then MTT treated and cultured for an additional 4 hours. Each value is the average of five independent experiments ± SD value.
Figures 3a-3d show the effect of TGF-? 1 (Figure 3a), BHcL (Figure 3b), LFs (Figure 3c) and LFi (Figure 3d) on fibroblast collagen type I synthesis. EC ₅₀ represents the concentration when the percentage of collagen type I synthesis is 200%. Each value represents the mean ± SD of five independent experiments. ^a p <0.01: compared with the control group LSD test, ^b p <0.01, and ^c p <0.05: EC ₅₀ as compared to the BHcL LSD test.
Figures 4a-4d show hyaluronidase inhibitory activity of OA (Figure 4a), BHcL (Figure 4b), LFs (Figure 4c) and LFi (Figure 4d). IC ₅₀ represents the concentration when the percentage of hyaluronidase activity is 50%. Each value represents the mean ± SD of five independent experiments. ^a p < 0.01 and ^b p < 0.05: ^c p < 0.01 and ^d p < 0.05 relative to control with LSD test. ^e p < 0.01 compared to control with MW test. Compared to IC50 of BHcL with MW test.
Figures 5a to 5d show the elastase inhibitory activity of PP (Figure 5a), BHcL (Figure 5b), LFs (Figure 5c) and LFi (Figure 5d). IC ₅₀ represents the concentration when the percentage of elastase activity is 50%. Each value represents the mean ± SD of five independent experiments. ^a p <0.01: Compared to control with LSD test, ^b p <0.01: compared to control with MW test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.
Figures 6a to 6d show collagenase inhibitory activity of OA (Figure 6a), BHcL (Figure 6b), LFs (Figure 6c) and LFi (Figure 6d). IC ₅₀ represents the concentration when the percentage of collagenase activity is 50%. Each value represents the mean ± SD of five independent experiments. ^a p <0.01: Compared to control with LSD test, ^b p <0.01: compared to control with MW test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.
Figures 7a to 7d show MMP-1 inhibitory activity of OA (Figure 7a), BHcL (Figure 7b), LFs (Figure 7c) and LFi (Figure 7d). IC ₅₀ represents the concentration when the percentage of MMP-1 activity is 50%. Each value represents the mean ± SD of five independent experiments. ^a p <0.01: Compared to control with LSD test, ^b p <0.01: compared to control with MW test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.
Figures 8a to 8d show tyrosinase inhibitory activity of arbutin (Figure 8a), BHcL (Figure 8b), LFs (Figure 8c) and LFi (Figure 8d). IC ₅₀ represents the concentration when the percentage of tyrosinase activity is 50%. Each value represents the mean ± SD of five independent experiments. ^a p <0.01 and ^b p <0.05 compared to control with LSD test, ^c p <0.01: compared to control with MW test, ^d p <0.01: compared to IC ₅₀ of BHcL with MW test.
9A to 9D show melanin formation inhibitory activities of arbutin (FIG. 9A), BHcL (FIG. 9B), LFs (FIG. 9C) and LFi (FIG. IC ₅₀ represents the concentration when the percentage of melanin production is 50%. Each value represents the mean ± SD of five independent experiments. ^a p < 0.01 and ^b p < 0.05: ^c p < 0.01 compared to control with LSD test. Compared to IC ₅₀ of BHcL with MW test.
FIG. 10 shows the skin moisture content of mice treated with no treatment or with BHcL, LFs or LFi. Each value represents the mean ± SD of five mouse skin. ^a p <0.01 and ^b p <0.05: no-treatment control group to the test compared to MW, ^c p <0.01, and ^d p <0.05: compared to skin treated with the LFs 0.167mg / cm ² to the test MW, ^e p <0.01: MW test Compared to skin treated with 0.167 mg / cm ² of LFi.

Hereinafter, the present invention will be described in more detail with reference to examples. These examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.

Comparative Example  One. Comparative example  Produce

Gold EunhwaLonicerae Flos) And indentationLonicerae Folium) Were purchased from Omniherb (Yeoungcheon, Korea). A total of 500 g of dried gold or porcelain was boiled in 5,000 ml of distilled water at 60 ° C for 3 hours for 3 times, evaporated, and lyophilized completely under reduced pressure. A total of 119.00 g (yield = 23.8%) of gold eutectic extract (LFs) and 113.5 g (yield = 22.7%) of phytotoxic extract (LFi) were obtained.

Example  1. Experimental material

(Sigma-Aldrich, St. Louis, MO, USA), TGF-? 1 powder (R & D System, Minneapolis, MN, USA), Phosphoramidon disodium salt USA) and solid OA (Oleanolic acid; Sigma, St. Louis, MO, USA) were used as positive control for skin regeneration, anti wrinkle or whitening effect, respectively.

Example  2. Hemai tree  Production of fruit extract

63 brix's buttocks ( Lonicera caerulea ) fruit juice concentrate was diluted with distilled water to 25 brix and then lyophilized under completely reduced pressure using a freeze drier (Operon FDB-5503, Kimpo, Korea) capable of performing a program operation to obtain 124.40 g (total yield: 62.2% Nuts extract (BHcL) was obtained. From the analysis of the components, it was confirmed that the BHcL was 380 kcal / 100 ml of energy, 93 g / 100 ml of carbohydrate, 41 g / 100 ml of protein, 2 g / 100 ml of protein and 200 mg / 100 ml of sodium, and total lipid, Cholesterol was not included. Further, the BHcL was found to have a betaine content of 4.54 ± 0.09%, a gallic acid equivalent of gallic acid equivalent of total phenol g, a catechin equivalent per gram of total flavonoid, 159.30 ± 12.51 mg of M3GE, and 133.57 ± 4.06 mg of malvidin-3-O-glucoside equivalent per gram of total anthocyanin.

Example  3. Cytotoxicity analysis

Human fibroblasts (fibroblast; CRL-2076; ATCC , Manassas, VA, USA) and B16 / F10 murine melanoma (melanoma) cells (CRL-6475; ATCC, Manassas , VA, USA) is 37 ℃, 5% CO ₂ (Gibco BRL, Grand Island, NY, USA), 100 units / ml penicillin (Sigma-Aldrich, St. Louis, MO, USA) and 100 μg / ml streptomycin (Sigma-Aldrich, (Sigma-Aldrich, St. Louis, MO, USA) containing DMEM (Sigma-Aldrich, MO, USA) The medium was replaced with fresh medium once every two or three days, and 0.05% trypsin-0.53 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA) was used for subculture. For B16 / F10 murine melanoma cells, 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA) was added to the medium. The cells were inoculated into a 24-well plate at 1 × 10 ⁵ cells / well and cultured at 37 ° C. and 5% CO ₂ . The next day, the medium was replaced with fresh medium containing 2% serum and cultured for 24 hours under the conditions of each sample (1.25, 2.5, 5, 10, 100 and 500 mg / ml) (Sigma-Aldrich, St. Louis, MO, USA). The cells were then incubated for an additional 4 hours. Then, the medium was removed and the produced MTT formazan was extracted with 1 ml of DMSO. Absorbance was measured at 570 nm (test wavelength) and 650 nm (reference wavelength) in a microplate reader (Tecan, Mannedorf, Switzerland). Cell viability was calculated by the following formula [1].

The formula [1]. Cell survival rate (%)

OD ₅₇₀ (specimen) / OD ₅₇₀ (control) x 100, where OD ₅₇₀ (specimen) is the absorbance at 570 nm of the treated cells and OD ₅₇₀ (control) is the absorbance at 570 nm of the untreated cells

Example  4. Prevention of skin aging, skin regeneration and Anti-wrinkle  effect

In the present invention, the anti-aging, skin regeneration and anti-wrinkle effects of the test specimens are confirmed by collagen type I synthesis analysis and hyaluronidase, elastase, collagenase and MMP-1 inhibition Respectively.

(One) EIA Kit  Collagen type I synthesis analysis using

Fibroblasts were inoculated into 24-well plates ( ⁵ x 105 cells / well) and cultured for 24 hours. Subsequently, the medium was replaced with serum-free IMDM (Iscove's modified Dulbecco's medium; Sigma-Aldrich, St. Louis, Mo., USA) and 0.0125, 0.025, 0.05, 0.1, 1 or 10 mg / ml test specimens (BHcL, LFs And LFi) or 0.1, 1, 10, 20, 40 or 100 ng / ml of TGF-? 1 and cultured for 24 hours. Controls were cultured without compound addition. After the culture, the culture medium was collected from each well and the amount of pro-collagen type I was measured at 450 nm in a microplate reader using a pro-collagen type IC peptide assay kit (Takara Bio, Tokyo, Japan) Respectively. Pro-collagen synthesis was calculated by the following formula [2], and the result is expressed as EC ₅₀ (the concentration at which the percentage of collagen type I synthesis is 200%).

The formula [2]. Pro-Collagen Synthesis (%)

= OD ₄₅₀ (sample) / OD ₄₅₀ (control group) × 100, where the OD ₄₅₀ (sample) is the absorbance in the treated sample cell 450nm, OD ₄₅₀ (control) is in the not treated with the sample cell 450nm Absorbance

(2) Hyaluronidase ( hyaluronidase ) Inhibition assay

Hyaluronidase reacts with the substrate hyaluronic acid to release N-acetyl glucosamine. When the inhibitor is present, the release of N-acetylglucosamine is reduced, which is observed by measuring the absorbance at 600 nm. The inhibitory activity of BHcL, LFs or LFi (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml) was compared to the standard OA under exactly the same experimental conditions. The 600 nm value of undissolved hyaluronic acid was taken as 100%. After 15 minutes of treatment, the OD value at 600 nm was measured with a 96-well microplate reader (Tecan, Mannedorf, Switzerland), and the hyaluronidase inhibitory activity of each sample was calculated by the following formula [3].

The formula [3]. Hyaluronidase inhibitory activity (%)

= 100 - {[(ODs + ODc) / ODc] x 100}, where ODs is the absorbance of the experimental specimen at 600 nm and ODc is the absorbance at 600 nm of the untreated control group

The above results are expressed as IC ₅₀ (concentration when hyaluronidase activity inhibition rate is 50%).

(3) Elastase ( elastase ) Inhibition assay

N-succinyl- (Ala) 3-p-nitroanilide (N-succinyl- (Ala) 3-p-nitroanilide) was synthesized by human leukocyte elastase (Sigma-Aldrich, St. Louise, As a result, p-glycoprotein was obtained under conditions in which BHcL was present (12.5, 25, 50, 100, 200 and 400 μg / ml) or PP (0.625, 1.25, 2.5, 5, 10 and 100 ng / Elastase inhibition assays were performed by measuring the release of nitroaniline. The absorbance at 410 nm was measured by a 96-well microplate reader. Elastase inhibitory activity of each sample was calculated by the following formula [4]. The results are expressed as IC ₅₀ (concentration when the percentage inhibition of elastase activity is 50%).

The formula [4]. Elastase inhibitory activity (%)

= 100 - [(ODs / ODc) x 100], where ODs is the absorbance at 410 nm of the experimental specimen and ODc is the absorbance at 410 nm of the untreated control group

(4) Collagenase  Inhibition assay

0.25 ml of 2 mM 4-phenylazobenzyloxycarbonyl-pro-leu-gly-pro-d-ar (Sigma-Aldrich, St. Louis, Mo., USA) in 0.1 M Tris-HCl buffer (pH 7.5) 1.5 ml of collagenase (1 mg / ml; Sigma-Aldrich, St. Louis, Mo., USA) was added to a mixed solution of 0.1 ml of the extract (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / Lt; 0 &gt; C for 20 minutes. The reaction was then stopped by the addition of 6% citric acid (Daejung, Seoul, Korea). After adding ethyl acetate (Sigma-Aldrich, St. Louis, Mo., USA), absorbance was measured at 320 nm with a UV / Vis spectrophotometer, and the collagenase inhibitory activity of each sample was calculated by the following formula [5] .

The formula [5]. Collagenase inhibitory activity (%)

= 100 - [(ODs / ODc) x 100], where ODs is the absorbance at 320 nm of the experimental specimen and ODc is the absorbance at 320 nm of the untreated control group

The results are expressed as IC ₅₀ (concentration when the inhibitory percentage of collagenase activity is 50%). OA (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml) were used as standards at exactly the same experimental conditions.

(5) MMP -1 inhibition assay

20 μl of Type-I collagen (substrate; Sigma-Aldrich, St. Louis, Mo., USA) was diluted with goat's milk, gilt silver or porcine extract or diluted with oleanolic acid as a standard (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml). 100 μl of diluted MMP-1 (0.2 U / ml; Sigma-Aldrich, St. Louis, Mo., USA) was then added to each well and the plates were incubated for 1-2 hours at room temperature under dark conditions. Fluorescence was measured at an excitation maxima of 495 nm and an emission maxima of 515 nm. All dilution procedures were performed with a reaction buffer at pH 7.6 containing 0.5 M Tris-HCl, 1.5 M NaCl, 50 mM CaCl ₂ and 2 mM sodium azide. A buffer containing substrate and inhibitor without MMP-1 was used as a control. The MMP-1 inhibitory activity of each sample was calculated by the following formula [6].

The formula [6]. MMP-1 inhibitory activity (%)

= 100 - [(ODs / ODc) x 100], where ODs is the absorbance at 515 nm of the experimental specimen and ODc is the absorbance at 515 nm of the untreated control group

The results are expressed as IC ₅₀ (the concentration at which the inhibitory percentage of MMP-1 activity is 50%).

Example  5. Whitening effect

In the present invention, the whitening effect of BHcL is evaluated by tyrosinase inhibitory assay and melanin formation test in B16 / F10 melanoma cells by comparing LFi and LFs and arbutin as a standard, Lt; / RTI &gt;

(One) Tyrosinase ( tyrosinase ) Inhibition assay

0.05 ml of BHcL, LFs or LFi (12.5, 25, 50, 100, 200 and 400 ug / ml) was added to 0.5 ml of L-DOPA (Sigma-Aldrich, St. Louise, MO, USA) solution (1.25 mM) (0.05 M, pH 6.8) and incubated at 25 ° C for 10 minutes. Then, 0.05 ml of an aqueous solution of mushroom tyrosinase (333 U / ml; Sigma-Aldrich, St. Louis, Mo., USA) was added to the mixed solution. Dopachrome formation was observed in the solution by measuring the linear increase at 475 nm OD with a UV / Vis spectrophotometer, and the tyrosinase inhibitory activity of each sample was calculated by the following formula [7]. The results are expressed as IC ₅₀ (concentration when the inhibitory percentage of tyrosinase activity is 50%). Arbutin (10, 20, 40, 80, 160 and 320 μg / ml) was used as a standard under exactly the same experimental conditions.

Formula [7]. Tyrosinase inhibitory activity (%)

= 100 - [(ODs / ODc) x 100], where ODs is the absorbance at 475 nm of the experimental specimen and ODc is the absorbance at 475 nm of the untreated control group

(2) Melanin formation test in B16 / F10 melanoma

B16 / F10 melanoma cells were inoculated and incubated overnight at 2xlO &lt; ⁵ &gt; cells / well in a 3-ml culture medium on a 6-well culture plate. The cells were incubated with various concentrations of BHcL, LFs, or LFi (50, 100, 200, 400, 800, and 100 mM) in the presence or absence of 100 nM alpha-MSH (alpha-melanocyte stimulating hormone, Sigma-Aldrich, St. Louis, 1,600 ug / ml) was added and cultured for 72 hours. After treatment, the cells were washed with PBS and lysed with 800 1 l IN NaOH (Merck, Darmstadt, Germany) containing 10% DMSO (Sigma-Aldrich, St. Louis, Mo., USA) . Absorbance was measured at 400 nm using a microplate reader. Melanogenesis inhibitory activity of each sample was calculated by the following formula [8]. The results are expressed as IC ₅₀ (concentration when the percentage of melanin production inhibition is 50%). Arbutin (20, 40, 80, 160, 320 and 640 占 퐂 / ml) was used as a standard under exactly the same experimental conditions.

The formula [8]. Melanin production inhibitory activity (%)

= 100 - [(ODs / ODc) x 100], where ODs is the absorbance of the experimental specimen at 400 nm and ODc is the absorbance at 400 nm of the control group treated with?

Example  6. In-vivo skin moisturizing effect

In the present invention, the skin moisturizing effect of the test specimen was confirmed by measuring changes in the skin moisture content of the mouse.

(1) Breeding of mice

Male SPF / VAF Outbred CrljOri: CD1 [ICR] mice (6 weeks old, OrientBio, Seungnam, Korea) were used in the experiment after 7 days adaptation period. The mice were housed in a room at 20-25 ° C temperature and 40-45% humidity conditions with 4 to 5 mice per group. Name: Cancer Cycle was 12 hours: 12 hours and fed standard rodent feed and water during the adaptation period. After the adaptation period, the non-treatment control group ^{mouse, LFs 0.167mg / cm 2, LFi} 0.167mg / cm 2, and BHcL 0.017, the group applying the 0.083 and 0.167mg / cm ² topically, divided into six groups, 30 Eight mice per 6 time points of minutes, 1, 2, 4, 8 and 24 hours were grouped by body weight.

(2) Processing

BHcL was dissolved in distilled water at concentrations of 1, 5 and 10 mg / ml, and LFs or LFi was dissolved in distilled water at a concentration of 10 mg / ml. Then 100 μl of distilled water, LFs or LFi (0.167 mg / cm ² ) or three concentrations of BHcL (0.017, 0.083 and 0.167 mg / cm ² ) were applied directly to the ² × ³ cm area of the dorsal skin Respectively. After 30 minutes of application, all remaining specimens were removed with cotton.

(3) Measurement of skin moisture content

2 × 3 cm of skin was removed after 0.5, 1, 2, 4, 8 and 24 hours from the sample application, and skin moisture content (%) was measured with an automated moisture analyzers balance (MB23, Ohaus, Pine Brook, NJ, USA) Respectively. In addition, to help understand the efficiency of the test specimen, the percent change relative to the untreated control was calculated by the following formula [9].

The formula [9]. % Change compared to untreated control (%)

= [((Data of sample-treated group - data of untreated control group) / data of untreated control group) x 100]

Example  7. Statistical Analysis

All in vitro data were expressed as the mean ± SD of five independent experiments, and the skin moisture content was expressed as the mean ± SD of 8 mouse skin at each time point. Multiple comparison tests were performed on groups of varying doses. Variance homogeneity was investigated using the Levene test. The data obtained were analyzed by least-significant differences (LSD) multi-comparison test after one-way ANOVA test to determine which group pair of group comparisons were different when Levene test results were deviating significantly from variance homogeneity . In addition, non-parametric comparison tests and Kruskal-Wallis H tests were performed when significant deviations from the variation homogeneity were observed in the Levene test. When significant differences were observed in the Kruskal-Wallis H test, the Mann-Whitney U-Wilcoxon Rank Sum W test was performed to determine specific group pairs with significantly different differences. In each in vitro assay, EC ₅₀ or IC ₅₀ values were calculated using the Probit method and statistical analysis was performed using SPSS for Windows (Release 14.0K, SPSS Inc., Chicago, IL, USA).

Experimental Example  1. Cytotoxicity

(1) Human fibroblast ( fibroblast )

There was no significant difference in human fibroblast survival rate from the treatment group of 1.25 mg / ml, which is the lowest treatment concentration of BHcL, LFs and LFi, to the treatment group of 500 mg / ml, which is the highest treatment concentration, compared to the control group without treatment (Figs.

(2) B16 / F10 Murine  Melanoma melanoma ) cell

There was no significant difference in B16 / F10 murine melanoma cell survival rate compared to the untreated medium control group from the lowest treatment concentration of BHcL, LFs and LFi to the treatment group of 1.25 mg / ml to the highest treatment concentration of 500 mg / ml To 2c).

In other words, it was confirmed that neither LFs nor LFi used for comparison as well as BHcL of the present invention show cytotoxicity, suggesting that BHcL can be safely used as a cosmetic composition, a pharmaceutical composition and a quasi-drug.

Experimental Example  2. Prevention of skin aging, skin regeneration and Anti-wrinkle  Check the effect

(1) Collagen type I synthesis effect

The increase in collagen type I productivity in the TGF-β1, BHcL, LFs and LFi treated groups was significant (p <0.01) compared to the untreated medium control groups from 1 ng / ml, 0.025, 0.05 and 0.05 mg / (LFi group) and EC ₅₀ (group TF-β1), 0.04 ± 0.03 mg / ml (group BHcL), 0.17 ± 0.07 mg / , particularly significant was recognized in a lower EC ₅₀ allows the BHcL treatment group (p <0.01 and p <0.05, respectively) compared to the LFs, and LFi treated group (Fig. 3a to 3d) was derived by. Therefore, BHcL can synthesize collagen type I more effectively than LFs and LFi.

(2) Hyaluronidase  Inhibitory activity

In significance relative to each control group from OA, BHcL, LFs, and LFi treatment group (p <0.01 or p <0.05) The hyaluronidase dehydratase activity inhibition is recognized from 0.0125, 0.0125, 0.025 and 0.05 mg / ㎖, the IC _50, respectively (LFs) and 0.07 ± 0.05 mg / ml (OA), 0.16 ± 0.08 mg / ml (BHcL) and 1.92 ± 0.97 mg / significantly compared to the IC ₅₀ of LFi (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (Fig. 4a to 4d). Therefore, BHcL can inhibit hyaluronidase activity more effectively than LFs and LFi.

(3) Elastase inhibitory activity

PP, BHcL, LFs, and (p <0.01) elastase dehydratase activity inhibition with significant compared to each control group from LFi treated group is recognized from 1.25 ng / ㎖, 0.0125, 0.05, and 0.05 mg / ㎖, IC ₅₀ is respectively 7.72 ± (LFs) and 3.48 ± 2.85 mg / ㎖ (LFi group), respectively. Especially, LFs and LFi were significantly higher than those of LFs IC _{50 values that} were significantly lower (p < 0.01) compared to IC ₅₀ were recognized in the BHcL treated group (Figures 5a-5d). Therefore, BHcL can inhibit elastase activity more effectively than LFs and LFi.

(4) Collagenase  Inhibitory activity

Inhibition of collagenase activity from OA, BHcL, LFs and LFi treatment groups was significantly higher than that of the control group (p <0.01), and IC _{50 values} were 0.04 ± 0.02 mg / (LFs), and the IC ₅₀ values of LFs and LFi were higher than those of LFs and LFi, respectively. (P < 0.01) lower IC ₅₀ was observed in the BHcL treated group (Figs. 6a to 6d). Therefore, BHcL can inhibit collagenase activity more effectively than LFs and LFi.

(5) MMP -1 inhibitory activity

0.05, 0.1, and 1 mg / ㎖, respectively, in the OA, BHcL, LFs, and LFi treated groups compared to the control group, and the IC _{50 values} were 0.38 ± 0.23 mg / (LF group), and the IC ₅₀ values of LFs and LFi were higher than those of LFs and LFi (OA group), 1.41 ± 0.92 mg / ml (BHcL group), 20.04 ± 10.65 mg / able to significantly than (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (FIG. 7a to 7d). Thus BHcL can suppress more effectively the activity of MMP-1 compared to the LFs, and LFi.

Taken together, BHcL increases collagen type I synthesis and inhibits the activity of hyaluronidase, elastase, collagenase and MMP-1, thereby providing excellent effects in preventing skin aging, regenerating skin and improving skin wrinkles have.

Experimental Example  3. Confirm whitening effect

(One) Tyrosinase  Inhibitory activity

25, 50 and 100 ㎍ / ㎖ inhibition of tyrosinase activity in the arbutin, BHcL, LFs and LFi treated groups, respectively (p <0.01 or p <0.05) IC _{50 values} were calculated as 74.69 ± 15.10 μg / ml (arbutin group), 124.43 ± 28.40 μg / ml (BHcL group), 244.03 ± 56.09 μg / ml (LFs group) and 421.66 ± 117.35 μg / ml It was able, in particular significance compared to the IC ₅₀ of the LFs and LFi (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (Fig. 8a to 8d). Therefore, BHcL can inhibit tyrosinase activity more effectively than LFs and LFi.

(2) melanin formation of B16 / F10 melanoma cells

The melanin production inhibition of B16 / F10 melanoma cells in the arbutin, BHcL, LFs and LFi treated groups was significantly (p <0.01 or p <0.05) significantly higher than that of the control group of 40, 200, 200 and 400 ㎍ / (BFcL group), 1,032.05 ± 156.71 μg / ml (LFs group), and 1,870.05 ± 482.14 μg / ml (LFi group), respectively, with IC _{50 values} of 173.67 ± 39.73 μg / ml (arbutin group), 489.27 ± 84.10 μg / was calculated as the group), in particular significantly compared to the IC ₅₀ of the LFs and LFi (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (Fig. 9a to 9d). Therefore, BHcL can inhibit melanin production more effectively than LFs and LFi.

Taken together, BHcL inhibits tyrosinase activity and inhibits melanin formation, and thus has excellent effects as a skin whitening composition.

Experimental Example  4. In vivo skin moisturizing effect confirmation

As compared with the distilled water group treated with control group, significant (p <0.01) increase in skin water content in, that the moisturizing effect is all BHcL 0.017, 0.083 and processed in the 0.167 mg / cm ² treatment group, 30 minutes after was recognized by coating a dose-dependent manner (P <0.01), respectively, in the 0.083 and 0.167 mg / cm ² treatment groups, respectively. In the 0.017 mg / cm ² treatment group, the increase in the skin moisture content was observed in the medium An increase in skin moisture content was recognized (p <0.01 or p <0.05) as compared to the control group. In the LFs and LFi and 0.167 mg / cm ² application groups, the skin moisture content was significantly increased (p <0.01 or p <0.05) compared with the vehicle control group. in BHcL treatment groups of 0.167 mg / cm ² in significance bihaeseodo the LFs and LFi and 0.167 mg / cm ² applied to the group (p <0.01 or p <0.05) respectively, an increase in skin moisture content up to 24 hours post-treatment after treatment 30 minutes It was acknowledged. On the other hand, in the group treated with 0.017 mg / cm ² of BHcL, an increase in skin moisture content similar to that of LFs and LFi and 0.167 mg / cm ^{2 was} observed from 30 minutes after treatment to 24 hours after treatment (Fig. 10).

In the LFs 0.167 mg / cm ² application group, the skin moisture contents after 30 minutes, 1, 2, 4, 8 and 24 hours were 17.49, 26.13, 21.27, 20.72, 16.90 and 9.77% And 16.48, 26.16, 24.49, 20.99, 20.45 and 7.43% in the LFi 0.167 mg / cm ² application group, respectively. The skin moisture content of BHcL 0.167 mg / cm ² treated group was 30.3 minutes, 1, 2, 4, 8, and 24 hours after treatment, respectively, compared to the control group, which was 33.36, 43.20, 44.60, 43.38, 43.92 and 33.94% , 0.083 mg / cm ² is applied in each group, respectively 28,19, 38.71, 40.21, 39.29, 38.11 and 33.60%, and 0.017 mg / cm ² treatment groups 21.19, 28.02, 25.61, 23.82, 20.51, and a change of 9.45% admit .

In conclusion, BHcL can be more effective for skin moisturization in vivo than LFs and LFi, and can be used as a skin moisturizing composition.

From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.

Claims (6)

Lonicera tree The present invention relates to a cosmetic composition for prevention of skin aging, regeneration of skin, improvement of wrinkles of skin or moisturization of skin, which contains fruit extract of caerulea as an active ingredient.
The composition according to claim 1, wherein the isola extract is extracted with water, an organic solvent or a mixed solvent thereof.
The composition of claim 1, further comprising an excipient for cosmetics.
The composition of claim 1, wherein the composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray &Lt; / RTI &gt;
Lonicera tree The present invention relates to a pharmaceutical composition for skin regeneration, which comprises a fruit extract as an active ingredient.
Lonicera tree caerulea ) Contains extracts of fruit as active ingredients to prevent skin aging, regenerate skin, improve skin wrinkles or skin moisturizers.

Images